Payment overview · 2025
General Payments
$1,290.97
66 reported records · 19 companies
Healthcare provider profile · identity verified
Daniel E Fortier, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WEST PALM BEACH, FL · NPI 1932173390
Verified facts
What the public records show
CMS Open Payments records show Daniel E Fortier, M.D. received $1,290.97 in general payments during 2025 across 66 reported records.
PFIZER INC. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Paxlovid, Rexulti, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 412 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 412 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $183.61 | 14.2% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $181.91 | 14.1% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.51 | 11.6% | 11 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $122.50 | 9.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $100.79 | 7.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $88.75 | 6.9% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $76.88 | 6.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $74.49 | 5.8% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $49.02 | 3.8% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $48.89 | 3.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.82 | 3.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.77 | 2.5% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.71 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.58 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.47 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.61 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.42 | 1.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.24 | 1.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.00 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,290.97 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $138.02 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $138.02 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $134.11 | 8 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $122.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $100.79 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $100.18 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $88.75 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $87.85 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $87.85 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $87.85 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.57 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $74.49 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $58.69 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $49.02 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $48.89 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.80 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.80 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $11.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 412 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 27 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
412 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
412 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 855 | 188 |
| Amlodipine Besylate | Amlodipine Besylate | 678 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 617 | 117 |
| Eliquis | Apixaban | 412 | 56 |
| Losartan Potassium | Losartan Potassium | 360 | 98 |
| Lisinopril | Lisinopril | 326 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 80 |
| Omeprazole | Omeprazole | 279 | 64 |
| Trazodone Hcl | Trazodone Hcl | 277 | 51 |
| Furosemide | Furosemide | 274 | 67 |
| Potassium Chloride | Potassium Chloride | 268 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 54 |
| Gabapentin | Gabapentin | 238 | 52 |
| Metformin Hcl | Metformin Hcl | 238 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 52 |
| Alprazolam | Alprazolam | 232 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 55 |
| Sertraline Hcl | Sertraline Hcl | 223 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 201 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 42 |
| Famotidine | Famotidine | 192 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 47 |
| Xarelto | Rivaroxaban | 167 | 17 |
| Mirtazapine | Mirtazapine | 162 | 37 |
| Divalproex Sodium | Divalproex Sodium | 150 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 29 |
| Simvastatin | Simvastatin | 145 | 36 |
| Donepezil Hcl | Donepezil Hcl | 142 | 29 |
| Allopurinol | Allopurinol | 129 | 33 |
| Carvedilol | Carvedilol | 126 | 28 |
| Azithromycin | Azithromycin | 114 | 88 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 25 |
| Ezetimibe | Ezetimibe | 111 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 29 |
| Montelukast Sodium | Montelukast Sodium | 102 | 20 |
| Ozempic | Semaglutide | 95 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 93 | 12 |
| Lactulose | Lactulose | 91 | 23 |
| Memantine Hcl | Memantine Hcl | 90 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 88 | 59 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 86 | 35 |
| Atenolol | Atenolol | 84 | 23 |
| Linzess | Linaclotide | 83 | suppressed |
| Lorazepam | Lorazepam | 83 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 62 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 82 | 20 |
| Prednisone | Prednisone | 81 | 26 |
| Glipizide | Glipizide | 78 | 16 |
| Methylprednisolone | Methylprednisolone | 78 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 27 |
| Latanoprost | Latanoprost | 67 | 14 |
| Olanzapine | Olanzapine | 67 | 12 |
| Lamotrigine | Lamotrigine | 66 | suppressed |
| Finasteride | Finasteride | 63 | 17 |
| Jardiance | Empagliflozin | 62 | 12 |
| Levetiracetam | Levetiracetam | 62 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 62 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 60 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 60 | 15 |
| Myrbetriq | Mirabegron | 58 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Levofloxacin | Levofloxacin | 57 | 35 |
| Synthroid | Levothyroxine Sodium | 57 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 26 |
| Ibuprofen | Ibuprofen | 54 | 16 |
| Nifedipine Er | Nifedipine | 54 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 21 |
| Sucralfate | Sucralfate | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 11 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Baclofen | Baclofen | 44 | 13 |
| Haloperidol | Haloperidol | 44 | suppressed |
| Methimazole | Methimazole | 44 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 18 |
| Clonidine Hcl | Clonidine Hcl | 41 | 14 |
| Torsemide | Torsemide | 41 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Cephalexin | Cephalexin | 39 | 31 |
| Glimepiride | Glimepiride | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 29 |
| Nystatin | Nystatin | 33 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 17 |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Ertapenem | Ertapenem Sodium | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 18 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | 13 |
| Prolia | Denosumab | 28 | 18 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 25 |
| Valacyclovir | Valacyclovir Hcl | 27 | 18 |
| Mesalamine | Mesalamine | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Erythromycin | Erythromycin Base | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Austedo Xr | Deutetrabenazine | 22 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 14 |
| Mupirocin | Mupirocin | 22 | 15 |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 18 |
| Restasis | Cyclosporine | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Diazepam | Diazepam | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 17 | suppressed |
| Ingrezza | Valbenazine Tosylate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Restasis Multidose | Cyclosporine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,290.97 · 66 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, Da Vinci Surgical System, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, INTERSTIM, JARDIANCE, Kerendia, MOUNJARO, MYFEMBREE, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, Rybelsus, Tymlos, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error